Predictive Factors and Value of ypN plus after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer

被引:3
|
作者
Fukada, Ippei [1 ]
Araki, Kazuhiro [1 ]
Kobayashi, Kokoro [1 ]
Shibayama, Tomoko [1 ]
Takahashi, Shunji [2 ]
Horii, Rie [3 ]
Akiyama, Futoshi [4 ]
Iwase, Takuji [5 ]
Ohno, Shinji [6 ]
Hatake, Kiyohiko [7 ]
Hozumi, Yasuo [8 ]
Sata, Naohiro [9 ]
Ito, Yoshinori [1 ]
机构
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Med Oncol, Tokyo, Japan
[2] Japanese Fdn Canc Res, Canc Inst Hosp, Med Oncol, Tokyo, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Div Pathol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo, Japan
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Breast Surg Oncol, Tokyo, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
[7] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol & Oncol, Tokyo, Japan
[8] Ibaraki Cent Hosp, Dept Surg, Ibaraki, Japan
[9] Jichi Med Univ, Dept Gastrointestinal Surg, Shimotsuke, Tochigi, Japan
来源
PLOS ONE | 2016年 / 11卷 / 09期
关键词
INTERNATIONAL EXPERT CONSENSUS; PREOPERATIVE CHEMOTHERAPY; PRIMARY THERAPY; RECOMMENDATIONS; PACLITAXEL; HIGHLIGHTS; DOCETAXEL; SUBTYPES; UPDATE; TRIAL;
D O I
10.1371/journal.pone.0162616
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are several definitions according to a variety of classifications. Eradication of cancer cells in both breast and lymph nodes has been better associated with improved prognosis than in the breast alone. Even in patients diagnosed as having clinically node-negative cancer before NAC, postoperative pathological examination often shows axillary lymph node metastases. Patients and Methods Of the 771 patients with breast cancer who underwent NAC in the Cancer Institute Hospital between January 2000 and May 2009, 146 patients preoperatively diagnosed as having node-negative breast cancer were retrospectively evaluated. We have made the definition of clinically lymph node-negative (N0) as follows: first, ultrasonography before NAC did not show any lymphadenopathy. Second, a cytological procedure confirmed negative study for each patient when ultrasonography suggested lymphadenopathy. Results The median observation period was 79.7 months, and the median age of the subjects was 51 years. Pathological examination at the time of the surgery showed lymph node metastases (ypN+) in 46 patients (31.5%). Histological therapeutic effects revealed ypT0/is in 9 patients (6.2%) and ypTinv in 137 (93.8%). Multivariate analysis demonstrated that younger age (49>), large tumor size, NG3, and ypN+ were significant poor prognostic factors for DFS (p = 0.020, p = 0.008, P = 0.022 and p = 0.010, respectively). Moreover, ypN+ was the only significant poor prognostic factor for OS (p = 0.022). The predictive factors of ypN+ in clinically lymph node-negative breast cancer were ypTinv (p = 0.036) and the luminal type (HR+ and HER2-) (p = 0.029). Conclusion The prognosis of clinically lymph node negative breast cancer depended on ypN+, which was associated with ypTinv and luminal subtype.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Predictive factors and value of ypN plus after neoadjuvant chemotherapy in clinically lymph node-negative breast cancer
    Fukada, I.
    Ito, Y.
    Kobayashi, K.
    Shibayama, T.
    Miyamoto, K.
    Takahashi, S.
    Horii, R.
    Akiyama, F.
    Iwase, T.
    Ohno, S.
    BREAST, 2017, 32 : S92 - S92
  • [2] Factors Associated with Axillary Lymph Node Status in Clinically Node-Negative Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Yu, Chi-Chang
    Cheung, Yun-Chung
    Ueng, Shir-Hwa
    Lin, Yung-Chang
    Kuo, Wen-Ling
    Shen, Shih-Che
    Lo, Yung-Feng
    Chen, Shin-Cheh
    CANCERS, 2022, 14 (18)
  • [3] Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer
    van der Noordaa, M. E. M.
    van Duijnhoven, F. H.
    Cuijpers, F. N. E.
    van Werkhoven, E.
    Wiersma, T. G.
    Elkhuizen, P. H. M.
    Winter-Warnars, G.
    Dezentje, V
    Sonke, G. S.
    Groen, E. J.
    Stokkel, M.
    Peeters, M. T. E. D. Vrancken
    BRITISH JOURNAL OF SURGERY, 2021, 108 (06) : 667 - 674
  • [4] Predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically node negative breast cancer.
    Jones, JL
    Rhei, E
    Gadd, MA
    Howard-Mcnatt, M
    Hughes, KS
    Lesnikoski, BA
    Christian, RL
    Rabban, JT
    Kaelin, C
    Smith, BL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 28S - 28S
  • [5] Sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node-negative breast cancer patients.
    Enokido, K.
    Nakamura, S.
    Tsugawa, K.
    Kojima, Y.
    Iwata, H.
    Ohno, S.
    Akiyama, F.
    Motomura, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [6] Identification of Sentinel Lymph Nodes in Clinically Node-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    So, Alycia
    Yi, Min
    Singh, Puneet
    Kuerer, Henry M.
    Lucci, Anthony, Jr.
    Caudle, Abigail
    Hwang, Rosario
    Huo, Lei
    Teshome, Mediget
    Hunt, Kelly K.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2024, 239 (05) : S62 - S62
  • [7] Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy
    So, Alycia
    Yi, Min
    Kuerer, Henry M.
    Caudle, Abigail
    DeSnyder, Sarah
    Bedrosian, Isabelle
    Smith, Benjamin D.
    Chavez-MacGregor, Mariana
    Litton, Jennifer
    Teshome, Mediget
    Hunt, Kelly K.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S92 - S93
  • [8] Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy
    Allen, Lisa R.
    Gadgil, Pranjali V.
    Bassett, Roland
    Hunt, Kelly
    Mittendorf, Elizabeth Ann
    Yi, Min
    Babiera, Gildy
    Kuerer, Henry Mark
    Ross, Merrick I.
    Bedrosian, Isabelle
    Meric-Bernstam, Funda
    Hwang, Rosa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [9] Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?
    Murphy, Brittany L.
    Jakub, James W.
    Asaad, Malke
    Day, Courtney N.
    Hoskin, Tanya L.
    Habermann, Elizabeth B.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (02) : 888 - 893
  • [10] Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?
    Brittany L. Murphy
    James W. Jakub
    Malke Asaad
    Courtney N. Day
    Tanya L. Hoskin
    Elizabeth B. Habermann
    Judy C. Boughey
    Annals of Surgical Oncology, 2021, 28 : 888 - 893